title: Aligning the economic value of companion diagnostics and stratified medicines.
abstract: The twin forces of payors seeking fair pricing and the rising costs of developing new medicines has driven a closer relationship between pharmaceutical companies and diagnostics companies, because stratified medicines, guided by companion diagnostics, offer better commercial, as well as clinical, outcomes. Stratified medicines have created clinical success and provided rapid product approvals, particularly in oncology, and indeed have changed the dynamic between drug and diagnostic developers. The commercial payback for such partnerships offered by stratified medicines has been less well articulated, but this has shifted as the benefits in risk management, pricing and value creation for all stakeholders become clearer. In this larger healthcare setting, stratified medicine provides both physicians and patients with greater insight on the disease and provides rationale for providers to understand cost-effectiveness of treatment. This article considers how the economic value of stratified medicine relationships can be recognized and translated into better outcomes for all healthcare stakeholders.
authors.affiliation: Integrated Medicines Ltd., Topfield House, Ermine Street, Caxton, Cambridge, CB23 3PQ, UK. eddie.blair@integratedmedicines.co.uk.
authors.forename: Edward D
authors.initials: ED
authors.lastname: Blair
authors.affiliation: Integrated Medicines Ltd., Topfield House, Ermine Street, Caxton, Cambridge, CB23 3PQ, UK. elyse.stratton@integratedmedicines.co.uk.
authors.forename: Elyse K
authors.initials: EK
authors.lastname: Stratton
authors.affiliation: Integrated Medicines Ltd., Topfield House, Ermine Street, Caxton, Cambridge, CB23 3PQ, UK. martina.kaufmann@integratedmedicines.co.uk.
authors.forename: Martina
authors.initials: M
authors.lastname: Kaufmann